Our Mission: Zero time waiting lists for kidney patientsDialysis patients stay for years on a kidney transplant waiting list with a very low quality of life, risking death and generating high costs to the community.
Our Mission: Zero time waiting lists for kidney patients
Dialysis patients stay for years on a kidney transplant waiting list with a very low quality of life, risking death and generating high costs to the community.
Our Vision & Mission
Advances in medicine have led to greater success in transplantation. On the other hand, an ageing society led to increasing numbers of patients on transplant waiting lists. Accordingly, availability of organs is less than adequate, and organ shortage has resulted in many cases of death.
For end-stage renal disease a kidney transplantation is the optimal therapy. Patients’ quality of life is increased, average life expectancy is prolonged, and healthcare costs are reduced. Today, due to shortage of transplant kidneys, each year many patients die, and many more suffer the debilitating effects of dialysis.
Our vision is to improve transparency and efficiency of organ transplantation workflows by democratizing access to state of the art medicine and boosting organ donations.
Our first mission is to reduce waiting time for end-stage renal disease patients for a better life.
The medical need
Dialysis patients stay for years on kidney transplant waiting lists with low quality of life, risking death and generating high costs.
Kidney transplantation offers significant advantages compared to prolonged dialysis.
Increased life expectancy
For dialysis after 5 years the mortality rate is 60 %. In contrast, for kidney transplantation it is 3 %.
A better quality of life
Quality of life is more than doubled. Clinical studies show 8 quality adjusted life years (QALY) for kidney transplantation, as opposed to just 3 QALY for dialysis.
For a 10 years period dialysis costs around 3 times more (>€900’000) then post-surgery care after kidney transplantation (>€300’000).
Our solution for kidney patients
The Organ.care navigator is a smartphone app which supports kidney patients from donor matching to post-transplantation care. Patients are empowered to connect with organ donors, friends, family, insurer, doctors and other healthcare professionals.
Benefits for patients
- Reduction of waiting time
- Improvement of organ matching
- Improvement of quality of life
- Health literacy
- Saving of lives
Benefits for the community
- Reduction of overall costs
- Transparency for organ donors
- Improvement of organ donation process
Benefits for healthcare providers
- Improvement of transparency and efficiency of clinical workflows
- Improvement of decision making
- Improvement of communication
The Organ.care navigator is a smartphone app for patients. It supports patients to connect with all relevant stakeholders and guides through the healthcare workflows. It is designed to integrate frictionless into a patient-centric healthcare ecosystem, and unlocks the power of data-driven healthcare.
Some statistics for the European Union
43’000’000’000 € total annual hemodialysis cost in the European Union for 490’000 patients with ESRD.
patients in the European Union are on the waiting list.
kidneys have been donated for transplantation in the EU in 2017.
are the costs of dialysis during the average waiting time of 3 years before transplantation.
are the costs of a kidney transplantation including 3 years of post-surgery care.
patients die each year on the waiting list.
is the mortality rate of dialisys after 5 years.
is the mortality rate of transplantation after 5 years.
of the total healthcare costs are accounted by 1% of the population (ESRD kidney patients).
Dr. Marcos Garcia Pedraza
Marcos lives in Switzerland, is a Swiss-Spanish entrepreneur and co-founded Organ.care with Paolo Lazzeri. He has over 20 years of experience in building technology-driven companies mainly in healthcare, was trained in life sciences at the Swiss Federal Institute of Technology (ETH) in Zurich, in entrepreneurship at Babson College in Boston, and holds a PhD in business economics from the University of St.Gallen. Marcos was honoured in 2002 with the E&Y Entrepreneur of the Year Award, in 2006 the SWITCH Innovation Award and 2007 the Telefonica VIDA Award. Marcos’ passions are contemporary art and wild nature.
He always had a passion for innovation and problem solving and has developed solutions to risk assessment and management whilst working as a helicopter pilot in remote camps. He has been flying as a bush pilot throughout the Canadian Arctic supporting mining exploration and in Western Africa as a VVIP pilot. A severe chronic illness forced him to change his career and he opted for a more “sedentary” but nevertheless challenging path. Paolo also served as a member of the Board of Directors at Lazzeri Agricola srl.
Paolo is a graduate from the Swiss Federal Institute of Technology (ETH) in Zurich from where he obtained a MS degree in Biochemistry.
Dr. Erich Odermatt
Erich was trained in microbiology, biochemistry and biophysical chemistry. He has over 30 years of industrial experience in the development of medical devices, production, QA/QC, registration (class I to III), and execution of clinical studies phase I to IV in different countries. Erich is member of different professional committees and boards, and co-author of over 80 patents and 50 publications.
Alfonso has an extensive international experience in the field of insurance services. His expertise lies in several insurance-related fields such as: Primary insurance, life, accident & health insurance, reinsurance, alternative risk transfer, and risk & capital management. He was trained in physics at the Swiss Federal Institute of Technology Zürich (ETH) in Zurich and has an entrepreneurial spirit. Currently he works in Zürich for a multinational life insurer as head of underwriting.
Dr. Benjamin Ambar
Benjamin has considerable experience as an investor and is an accomplished serial entrepreneur. As an early crypto adopter he built up an extensive knowledge about blockchain and token economy.
He holds a Master in Neuroscience from ETH Zurich and a PhD in Biochemistry from University of Zurich.
HUMAN TRAFFICKING, THE HAITI FILES May 1, 2018 Organ trafficking is an undeniable worldwide issue that has been around since pharmaceuticals were first introduced in 1970 to prevent organ rejection, and quite possibly even earlier. The numbers speak for...
The state of the international organ trade: a provisional picture based on integration of available information
by Yosuke Shimazono Introduction Organ transplantation is an effective therapy for end-stage organ failure and is widely practised around the world. According to WHO, kidney transplants are carried out in 91 countries. Around 66 000 kidney transplants, 21 000 liver...
An opt-out register is unlikely to increase the number of organ donations because family members would be more likely to veto a presumed consent, researchers have said. The results of a study by Queen Mary University of London suggest that next of kin are more likely...